[A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
We report a case in which chemotherapy with paclitaxel (TXL) infused systemically and intraperitoneally was effective for gastric cancer with malignant ascites. A 69-year-old man suffering from advanced gastric cancer with peritoneal dissemination underwent distal gastrectomy, a radical C operation. After chemotherapy with TS-1 and low-dose CDDP, TS-1 was administrated on an outpatient basis for 6 months. However, he complained of abdominal fullness and ascites, and received combination chemotherapy with paclitaxel infused systemically and intraperitoneally as second-line treatment. The ascites completely disappeared 5 weeks after administration. The only toxic event was anemia (grade 1), and no major adverse effects were observed.
Morifuji
Masahiko
M
Dept. of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University.
Murakami
Yoshiaki
Y
Yokoyama
Yujiro
Y
Sasaki
Masaru
M
Hayashidani
Yasuo
Y
Toge
Kunio
K
Sueda
Taijiro
T
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001201:Ascites / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D008297:Male; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel